Compare Freeport-McMoRan Inc (FCX) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Neurocrine Biosciences Inc — how do they compare? Freeport-McMoRan Inc trades at $72.7 (market cap $103.19B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Freeport-McMoRan Inc is far larger — about 7.1× Neurocrine Biosciences Inc's market cap, and Freeport-McMoRan Inc pays a 0.83% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Freeport-McMoRan Inc for 69 Days and Neurocrine Biosciences Inc for 23 Days on average.
| FCX | NBIX | |
|---|---|---|
Market Cap | $103.19B | $14.60B |
Volume | 11,744,911 | 1,075,694 |
Sector | Basic Materials | Health |
52-Week High | $79.91 | $185.50 |
52-Week Low | $38.65 | $123.10 |
Typical Hold Time | 69 Days | 23 Days |
Enterprise Value | $109.47B | $14.61B |
Dividend Yield | 0.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $71.13, down 1.98% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $72.27. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Strong operating cash flow of $5.61 billion in 2025 supports ongoing expansion projects amid favorable copper demand trends.
The outlook for FCX is positive, driven by robust copper demand from AI and data center growth, but risks include rising production costs and a legal investigation. Wall Street sentiment is bullish with 61% buy ratings, though the stock faces near-term resistance at $72.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
